OCUL
Price
$12.55
Change
+$0.31 (+2.53%)
Updated
Sep 24, 04:59 PM (EDT)
Capitalization
2.13B
47 days until earnings call
VRNA
Price
$106.38
Change
+$0.13 (+0.12%)
Updated
Sep 24, 04:59 PM (EDT)
Capitalization
9.19B
48 days until earnings call
Interact to see
Advertisement

OCUL vs VRNA

Header iconOCUL vs VRNA Comparison
Open Charts OCUL vs VRNABanner chart's image
Ocular Therapeutix
Price$12.55
Change+$0.31 (+2.53%)
Volume$62.59K
Capitalization2.13B
Verona Pharma
Price$106.38
Change+$0.13 (+0.12%)
Volume$4.71K
Capitalization9.19B
OCUL vs VRNA Comparison Chart in %
Loading...
OCUL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
OCUL vs. VRNA commentary
Sep 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is OCUL is a Hold and VRNA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 25, 2025
Stock price -- (OCUL: $12.25 vs. VRNA: $106.25)
Brand notoriety: OCUL and VRNA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: OCUL: 92% vs. VRNA: 76%
Market capitalization -- OCUL: $2.13B vs. VRNA: $9.19B
OCUL [@Biotechnology] is valued at $2.13B. VRNA’s [@Biotechnology] market capitalization is $9.19B. The market cap for tickers in the [@Biotechnology] industry ranges from $97.36B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

OCUL’s FA Score shows that 0 FA rating(s) are green whileVRNA’s FA Score has 1 green FA rating(s).

  • OCUL’s FA Score: 0 green, 5 red.
  • VRNA’s FA Score: 1 green, 4 red.
According to our system of comparison, VRNA is a better buy in the long-term than OCUL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

OCUL’s TA Score shows that 4 TA indicator(s) are bullish while VRNA’s TA Score has 3 bullish TA indicator(s).

  • OCUL’s TA Score: 4 bullish, 5 bearish.
  • VRNA’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, both OCUL and VRNA are a bad buy in the short-term.

Price Growth

OCUL (@Biotechnology) experienced а -1.49% price change this week, while VRNA (@Biotechnology) price change was -0.02% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was +10.70%, and the average quarterly price growth was +54.52%.

Reported Earning Dates

OCUL is expected to report earnings on Nov 10, 2025.

VRNA is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Biotechnology (+4.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VRNA($9.19B) has a higher market cap than OCUL($2.13B). VRNA YTD gains are higher at: 128.790 vs. OCUL (43.443). VRNA has higher annual earnings (EBITDA): -34.62M vs. OCUL (-200.5M). VRNA has more cash in the bank: 438M vs. OCUL (391M). OCUL has less debt than VRNA: OCUL (76.9M) vs VRNA (244M). VRNA has higher revenues than OCUL: VRNA (222M) vs OCUL (56.7M).
OCULVRNAOCUL / VRNA
Capitalization2.13B9.19B23%
EBITDA-200.5M-34.62M579%
Gain YTD43.443128.79034%
P/E RatioN/AN/A-
Revenue56.7M222M26%
Total Cash391M438M89%
Total Debt76.9M244M32%
FUNDAMENTALS RATINGS
OCUL vs VRNA: Fundamental Ratings
OCUL
VRNA
OUTLOOK RATING
1..100
8385
VALUATION
overvalued / fair valued / undervalued
1..100
52
Fair valued
81
Overvalued
PROFIT vs RISK RATING
1..100
842
SMR RATING
1..100
9897
PRICE GROWTH RATING
1..100
4137
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
7585

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

OCUL's Valuation (52) in the Pharmaceuticals Other industry is in the same range as VRNA (81). This means that OCUL’s stock grew similarly to VRNA’s over the last 12 months.

VRNA's Profit vs Risk Rating (2) in the Pharmaceuticals Other industry is significantly better than the same rating for OCUL (84). This means that VRNA’s stock grew significantly faster than OCUL’s over the last 12 months.

VRNA's SMR Rating (97) in the Pharmaceuticals Other industry is in the same range as OCUL (98). This means that VRNA’s stock grew similarly to OCUL’s over the last 12 months.

VRNA's Price Growth Rating (37) in the Pharmaceuticals Other industry is in the same range as OCUL (41). This means that VRNA’s stock grew similarly to OCUL’s over the last 12 months.

VRNA's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as OCUL (100). This means that VRNA’s stock grew similarly to OCUL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
OCULVRNA
RSI
ODDS (%)
Bearish Trend 2 days ago
77%
Bearish Trend 2 days ago
72%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
78%
Momentum
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
74%
MACD
ODDS (%)
Bearish Trend 2 days ago
81%
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
79%
Advances
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 13 days ago
79%
Declines
ODDS (%)
Bearish Trend 8 days ago
85%
Bearish Trend 6 days ago
81%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
81%
Aroon
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
OCUL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GREZX9.560.04
+0.42%
GuideStone Funds Global Rl Est Secs Inv
CENTX14.27N/A
N/A
Centerstone Investors I
RGLAX27.66-0.03
-0.11%
American Funds Global Insight R-1
VRMCX61.73-0.19
-0.31%
Virtus KAR Mid-Cap Core R6
GITAX33.17-0.38
-1.13%
Goldman Sachs Technology Opps A

OCUL and

Correlation & Price change

A.I.dvisor indicates that over the last year, OCUL has been loosely correlated with EYPT. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if OCUL jumps, then EYPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OCUL
1D Price
Change %
OCUL100%
+0.41%
EYPT - OCUL
65%
Loosely correlated
+0.22%
NRIX - OCUL
56%
Loosely correlated
-2.25%
IDYA - OCUL
56%
Loosely correlated
+0.04%
CRNX - OCUL
55%
Loosely correlated
+6.35%
IMVT - OCUL
55%
Loosely correlated
-4.43%
More

VRNA and

Correlation & Price change

A.I.dvisor indicates that over the last year, VRNA has been loosely correlated with RYTM. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if VRNA jumps, then RYTM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VRNA
1D Price
Change %
VRNA100%
N/A
RYTM - VRNA
47%
Loosely correlated
-0.30%
IRON - VRNA
42%
Loosely correlated
+1.08%
ZYME - VRNA
42%
Loosely correlated
-1.03%
BBIO - VRNA
39%
Loosely correlated
-0.08%
OCUL - VRNA
36%
Loosely correlated
+0.41%
More